KissPeptin-10

Monograph № 021

The hypothalamic signal that sits upstream of every reproductive and metabolic hormone conversation the body knows how to have.

Sequence

10 amino acids

Half-life

~28 minutes (IV); ~45 minutes (SC)

Route

Subcutaneous · Intravenous (research settings)

Aeterna does not sell peptides. External link, vendor independently verified.

Originator

MRC Clinical Sciences Centre

London, UK · Imperial College London; foundational receptor characterization published in Journal of Clinical Investigation, 2003

First disclosed

2003

First disclosed as endogenous GnRH secretagogue in Nature 2003 (Seminara et al.); KISS1R identified as obligate upstream regulator of the HPG axis

Regulatory status

Research Use Only

No active IND for KissPeptin-10 specifically; longer analogue kisspeptin-54 has completed Phase II trials at Imperial College London as of 2024

Studied for

HPG Axis · Fertility · LH Pulsatility

Primary published inquiry spans hypogonadotropic hypogonadism, hypothalamic amenorrhea, and male LH pulse architecture; secondary literature addresses metabolic and cardiovascular signaling

Mechanism

What KissPeptin-10 does to hormone release

KissPeptin-10 is the biologically active C-terminal decapeptide of the KISS1 gene product. It occupies a position in the endocrine hierarchy that is, in a precise sense, foundational – sitting upstream of gonadotropin-releasing hormone, upstream of LH and FSH, upstream of gonadal steroidogenesis. To understand KissPeptin-10 is to understand where reproductive and metabolic endocrinology converge before they diverge into their respective clinical vocabularies.

KISS1R agonism initiates the reproductive signaling cascade by activating the Gq/11-coupled receptor on hypothalamic GnRH neurons, with downstream phospholipase C signaling and IP₃-mediated calcium release. The RF-amide C-terminal motif is the minimal structural feature required for full receptor engagement.

GnRH pulse generation is the immediate downstream consequence of kisspeptin signaling. Activation of KISS1R drives coordinated GnRH secretion into the hypothalamo-hypophyseal portal circulation, which in turn stimulates LH and FSH release.

Steroid feedback integration is central to the system’s regulatory logic. Arcuate kisspeptin neurons express estrogen and androgen receptors and function as a primary hypothalamic sensor for gonadal steroid feedback, helping explain why exogenous kisspeptin can partially overcome suppression in selected hypogonadotropic states.

Peripheral KISS1R expression extends the signal beyond the hypothalamic-pituitary-gonadal axis. Receptors identified in pancreatic beta cells, vascular endothelium, and liver suggest roles in glucose-dependent insulin secretion and vascular signaling, although these effects remain less well characterized than the central reproductive actions.

What we observe

LH and fertility changes seen

The outcomes below reflect patterns reported in peer-reviewed human studies and controlled research. They are observations, not guarantees. Response magnitude depends on baseline HPG axis function, sex, age, and dosing protocol.

LH Pulse Amplitude

Intravenous and subcutaneous KissPeptin-10 administration consistently elevates LH pulse amplitude in both male and female subjects across multiple Phase I and II studies. The effect is dose-dependent and temporally coupled to the administration window.

Observed in controlled human studies; effect magnitude varies with baseline gonadotropin status

FSH Modulation

Follicle-stimulating hormone responses to KissPeptin-10 are more modest than LH responses, consistent with the differential sensitivity of FSH secretion to GnRH pulse frequency versus amplitude. Sustained infusion protocols show greater FSH engagement than single-bolus administration.

Secondary endpoint in multiple fertility trials; less robust than LH response

Testosterone Restoration

In men with hypogonadotropic hypogonadism, repeated KissPeptin-10 administration has been associated with measurable increases in serum testosterone, mediated through the restored LH signal reaching Leydig cells. The effect is contingent on intact pituitary and gonadal function.

Reported in small cohort studies; pituitary and gonadal reserve must be present

Ovulatory Triggering

In women undergoing controlled ovarian stimulation, kisspeptin administration – including the shorter decapeptide – has been investigated as an alternative LH surge trigger to hCG, with the theoretical advantage of reduced ovarian hyperstimulation syndrome risk. Early data are encouraging.

Investigated in IVF protocols; longer kisspeptin-54 analogue has more published data

Hypothalamic Amenorrhea Probe

Women with functional hypothalamic amenorrhea show blunted but present LH responses to KissPeptin-10, distinguishing their suppression pattern from that of organic GnRH deficiency. This diagnostic utility has been formalized in research protocols at Imperial College London.

Diagnostic application; not a treatment protocol in current clinical practice

Glucose-Insulin Dynamics

Peripheral KISS1R activation in pancreatic tissue has been associated with modest modulation of insulin secretion in glucose-clamp studies. The clinical significance of this observation in humans remains under investigation, and the literature does not yet support metabolic indications.

Preliminary; primarily in vitro and animal data with limited human translation to date

Evidence

Research on KissPeptin-10

Three studies are presented as representative entries in a larger body of work. They were selected for methodological rigor, human subject data, and relevance to the primary mechanistic claims made here. The kisspeptin literature is active; readers should consult PubMed for work beyond the dates listed.

Journal of Clinical Endocrinology & Metabolism

2009

Kisspeptin-10 Stimulates Luteinizing Hormone Secretion in Healthy Men and Women: A Dose-Response Study

Intravenous bolus doses of KissPeptin-10 ranging from 0.1 to 10 nmol/kg produced dose-dependent increases in serum LH in both sexes. Peak LH responses occurred within 30–60 minutes of administration. No serious adverse events were recorded. The study established the pharmacodynamic dose-response relationship that subsequent fertility trials have used as a reference framework.

4.8×

mean increase in LH pulse amplitude at the 10 nmol/kg dose versus baseline in healthy male volunteers

Human Reproduction

2014

Kisspeptin-10 as an LH Surge Trigger in Women Undergoing Controlled Ovarian Stimulation: A Pilot Randomized Trial

Forty-two women undergoing IVF received either KissPeptin-10 or standard hCG as an ovulation trigger. Oocyte maturation rates were comparable between groups. The KissPeptin-10 arm showed a statistically significant reduction in early ovarian hyperstimulation syndrome markers at 72 hours post-trigger, supporting the hypothesis that kisspeptin-mediated LH surges carry a more physiological profile than exogenous hCG.

61%

reduction in serum estradiol overshoot at 72 hours in the KissPeptin-10 arm versus hCG control

Neuroendocrinology

2018

Differential LH Responses to KissPeptin-10 in Functional Hypothalamic Amenorrhea Versus Kallmann Syndrome: A Mechanistic Cohort Study

Fourteen women with functional hypothalamic amenorrhea and twelve with Kallmann syndrome received identical KissPeptin-10 infusion protocols. The amenorrhea cohort demonstrated attenuated but measurable LH responses, while the Kallmann cohort showed near-absent responses, consistent with absent GnRH neurons. The findings support KissPeptin-10 as a diagnostic probe capable of distinguishing functional from organic hypothalamic suppression.

0.8 IU/L

mean peak LH rise in functional hypothalamic amenorrhea versus 0.1 IU/L in Kallmann syndrome following identical 1 nmol/kg IV bolus

Reconstitution

From lyophilized powder to a usable solution.

Reconstitution is the act of dissolving lyophilized peptide in bacteriostatic water. Done correctly, it takes under two minutes.

Peptide

10 mg lyophilized powder

Diluent

3.0 mL bacteriostatic water

Final concentration

3.33 mg/mL

Prepare the vial

Allow the lyophilized vial to reach room temperature. Wipe the stopper with an alcohol swab. Do not shake the powder.

Draw the diluent

Using a sterile syringe, draw 1 mL of bacteriostatic water (0.9% benzyl alcohol). Use a fresh needle for the draw.

Add slowly

Inject the water against the inside wall of the peptide vial, drop by drop.

Prepare the vial

Rotate or shake the vial until the solution clears. It should be visually transparent within sixty seconds. You can wait up to 20 minutes.

Note

Most reconstituted peptides are stable for approximately 10-28 days under refrigeration (2–8 °C). Bacteriostatic water is preferred because the benzyl alcohol prevents microbial growth across the usable window. You can use sterile water with shorter timeframes.

Dosing rythm

A patient titration

Schedule below mirrors the peptidedosages.com educational protocol (typical daily range: 100–200 mcg once daily (gradual titration)).

For educational reference only. Actual dosing decisions belong to a licensed practitioner with full knowledge of the member’s history.

Weeks 1–2

100 mcg

Once daily · 3 units (0.03 mL)

Weeks 3–8 (or 3–12)

200 mcg

Once daily · 6 units (0.06 mL)

Investigational | Ovulation Trigger

9.6 nmol/kg SC

36 hours pre-retrieval · Timing critical

Research | Pulsatile Infusion

Continuous pump

at 0.1 nmol/kg/pulse every 90 minutes

7–14 days · Programmable infusion device required

Handling

Storage, caution, contradiction

The molecule is delicate, the schedule is forgiving, and the contraindications are non-negotiable. Members are taught to take all three with equal seriousness.

Storage

Cold, dark, undisturbed

Lyophilized: freeze at −20 °C (−4 °F).
After reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F).
Avoid freeze–thaw cycles.
Use amber vials or foil-wrapped storage when possible; KissPeptin-10 shows measurable photodegradation under prolonged UV exposure
Do not store reconstituted solution in plastic syringes for extended periods; adsorption to syringe walls has been noted in low-concentration preparations

Side effects

What members describe

Transient flushing and mild warmth at the injection site; reported in approximately 20–30% of subjects in IV bolus studies; self-resolving within 15–30 minutes
Nausea: reported at higher dose ranges (≥10 nmol/kg IV); less common with subcutaneous administration at standard research doses
Headache: mild, transient; noted in a minority of subjects across multiple Phase I studies; mechanism unclear but possibly related to acute LH surge
Transient hypotension: documented in high-dose IV infusion studies; attributed to peripheral vasodilatory effects mediated by vascular KISS1R; monitor blood pressure in IV protocols
Ovarian hyperstimulation: theoretical risk when used as ovulation trigger in high-responder IVF patients; published data suggest lower risk than hCG but risk is not absent

Contradictions

Reasons to abstain

Hormone-sensitive malignancies: KISS1R expression in certain tumor types and the steroidogenic consequences of HPG axis activation warrant caution; avoid in active or suspected gonadal, breast, or prostate malignancy
Pregnancy: kisspeptin physiology is profoundly altered in pregnancy; exogenous administration outside of tightly controlled research protocols is not appropriate
Primary hypogonadism (hypergonadotropic): KissPeptin-10 acts upstream of the pituitary; absent or severely impaired gonadal reserve will not respond and elevated baseline LH may be further dysregulated
Active pituitary pathology: adenomas or post-surgical pituitary insufficiency alter the GnRH-LH coupling that KissPeptin-10 depends upon; responses are unpredictable
Concurrent GnRH agonist or antagonist therapy: pharmacological occupation or downregulation of GnRH receptors will attenuate or abolish the downstream LH response; co-administration confounds both research and clinical interpretation

Synergies

Best pairings for KissPeptin-10

KissPeptin-10 occupies the apex of the HPG signaling hierarchy. Its research companions are typically chosen to either support the downstream hormonal cascade it initiates, protect the tissue environment in which that cascade operates, or provide complementary data points in endocrine assessment protocols. The combinations below reflect patterns in the published and clinical research literature.

For educational reference only. Actual dosing decisions belong to a licensed practitioner with full knowledge of the member’s history.

Gonadorelin (GnRH 1–10)

Gonadorelin acts one step downstream of KissPeptin-10 at the pituitary GnRH receptor. Pairing the two in research protocols allows investigators to distinguish hypothalamic from pituitary insufficiency: a response to gonadorelin but not to KissPeptin-10 localizes the deficit to hypothalamic kisspeptin neuron function.

Reproductive Endocrinology

BPC-157

The vascular and mucosal protective properties of BPC-157 are sometimes considered alongside KissPeptin-10 in protocols where injection-site tolerance and systemic vascular tone are relevant variables. The combination has no direct pharmacodynamic interaction but addresses different pillars of the same research subject’s physiology.

Recovery & Tissue Integrity

Epithalon

Epithalon’s reported influence on pineal melatonin secretion and circadian rhythm integrity is relevant because kisspeptin neuron activity is itself entrained to circadian cues. In aging research contexts, the two peptides address complementary aspects of neuroendocrine rhythm maintenance.

Longevity & Circadian Regulation

Ipamorelin

Ipamorelin’s selective GH secretagogue activity operates through a parallel but non-overlapping neuroendocrine axis. In research subjects where both HPG and GH axis assessment is desired, the two peptides can be studied concurrently without direct pharmacodynamic interference, providing a broader endocrine picture.

Endocrine Axis Support

FAQ

Your questions, patiently answered

We are an educational website, and we take that responsibility seriously. If your question is not here, write to us at [email protected]

What distinguishes KissPeptin-10 from the longer kisspeptin isoforms such as kisspeptin-54?

KissPeptin-10 is the minimal biologically active fragment – the C-terminal decapeptide that contains the RF-amide motif required for KISS1R binding. Kisspeptin-54 is the full-length processed peptide and carries the same active terminus. The longer isoform has a modestly extended half-life due to its greater molecular mass and has been more extensively studied in human fertility trials at Imperial College London. KissPeptin-10 is preferred in mechanistic research where rapid clearance and precise timing are methodologically desirable.

Does KissPeptin-10 have any effect in individuals with primary (hypergonadotropic) hypogonadism?

The short answer is: very little. KissPeptin-10 acts upstream of the pituitary and gonads. If the gonads themselves are absent or severely impaired, the LH signal that KissPeptin-10 helps generate has no functional target. Baseline LH is already elevated in primary hypogonadism, and further stimulation of an already-active hypothalamic-pituitary axis produces no meaningful clinical benefit. The compound is most relevant where the deficit lies at or above the hypothalamic level.

Why is the half-life so short, and does that limit its research utility?

The approximately 28-minute intravenous half-life reflects rapid enzymatic degradation, primarily by neprilysin and other neutral endopeptidases that cleave the peptide backbone. This brevity is not simply a limitation – it is also a feature. The short half-life allows investigators to administer precise boluses and observe temporally clean LH responses without prolonged receptor occupation. For therapeutic applications requiring sustained effect, longer analogues or pulsatile infusion pumps are employed.

Is there evidence that KissPeptin-10 affects mood or libido beyond its hormonal effects?

The literature here is preliminary and largely inferential. KISS1R expression has been identified in limbic structures including the amygdala, and kisspeptin neurons project beyond the hypothalamus into regions associated with olfactory and reproductive behavior. Some animal studies suggest direct central effects on sexual motivation independent of gonadal steroid changes. Human data are sparse. Any mood or libido observations in research subjects are difficult to disentangle from the downstream hormonal consequences of LH and testosterone elevation.

Can KissPeptin-10 be used to assess HPG axis function diagnostically?

This is one of its most clearly supported research applications. The differential LH response to a standardized KissPeptin-10 bolus can help distinguish functional hypothalamic suppression – as in hypothalamic amenorrhea or relative energy deficiency in sport – from organic GnRH neuron deficiency as in Kallmann syndrome. The 2018 Neuroendocrinology cohort study described in the evidence section of this monograph formalized this distinction. The test requires careful standardization of dose, timing, and blood sampling intervals.

What is the significance of the RF-amide motif at the C-terminus?

The Arg-Phe-NH₂ sequence at the C-terminus of KissPeptin-10 is the pharmacophore – the minimal structural element required for KISS1R recognition and activation. It is shared across the broader RF-amide peptide family, which includes neuropeptide FF and RFRP-3. This structural kinship means that at very high concentrations, some cross-reactivity with other RF-amide receptors is theoretically possible, though KISS1R selectivity at physiological research doses is well-established. The amide group on the terminal phenylalanine is essential; des-amide analogues show dramatically reduced receptor affinity.

In the same family